title: Sickle cell anemia and hematopoietic cell transplantation: When is a pound of cure worth more than an ounce of prevention?
abstract: Hematopoietic cell transplantation (HCT) is curative therapy for sickle cell anemia (SCA). However, its widespread use is constrained by donor availability and by concerns about its short-term and long-term toxicities. Current efforts to identify suitable candidates for HCT to decrease the toxicity of HCT, and to broaden its availability are discussed.
authors.affiliation: Children's Hospital and Research Center, Oakland, Oakland, CA, USA. mwalters@mail.cho.org
authors.forename: Mark C
authors.initials: MC
authors.lastname: Walters
mesh_terms: D000755:Anemia, Sickle Cell / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D010372:Pediatrics; D014019:Tissue Donors / Q000600:supply & distribution